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Regional Hyperinsulinemia Induces Vasodilation But Does 
Not Modulate Adrenergic Responsiveness in Humans
Cees J. J. Tack, Marian Heeremans, Theo Thien, Jos A. Lutterman, and *Paul Smits
Division o f  General Internal Medicine, Department o f  Medicine, and *Department o f  Pharmacology, University
Hospital Nijmegen, Nijmegen, The Netherlands
Summary: The relation betw een  insulin resistance/ 
hyperinsulinemia and cardiovascular disease may be re­
lated to one of the cardiovascular effects o f insulin. In 
acute experiments in humans, systemic euglycemic hy- 
perinsulinemia induced vasodilation in skeletal muscle. 
Furthermore, the sympathetic nervous system is acti­
vated, although this does not lead to increase in blood 
pressure (BP). We hypothesized that insulin could induce 
vasodilation either by reduction of a- or by augmentation 
of p-adrenergic responsiveness. The effect of insulin in­
fusion into the brachial artery (regional forearm hyperin­
sulinemia; venous insulin concentration —500 pM) on 
forearm blood flow (FBF: plethysmography) was studied. 
Responses to the a-adrenoceptor-mediated vasoconstric­
tor norepinephrine (NE: once with and once without the p- 
adrenoceptor antagonist propranolol, 2 x  n =  12; 9 par­
ticipated in both), and to the p-adrenoceptor-mediated 
vasodilator isoproterenol (n = 1 2 ) were measured before 
and during local hyperinsulinemia. Time/control studies 
(n = 6 ) were performed. Insulin alone induced vasodila­
tion, as indicated by an increase in FBF'ratio (infused/ 
control arm) from 1 . 2  ±  0 . 1  to 1 . 6  ±  0 .2 , p =  0.009. 
Increasing dosages of N E  (1.25 to 240 ng * d l ' 1 • m l ' 1) 
induced vasoconstriction that was more pronounced dur­
ing concomitant propranolol infusion (p <  0 .0 0 1 ), indicat­
ing a dose-dependent vasodilatory component in the ef­
fect of NE. Isoproterenol (ISO 0.03 to 10 ng * dl~* ‘ ini'"1), 
a pure p-adrenoceptor agonist, induced vasodilation. The 
percentage changes of FBF-ratio during N E +  propran­
olol were similar and not significantly different before and 
during hyperinsulinemia. The same was true o f  the re­
sponse to N E  alone and the response to ISO. Neither was 
the intrinsic p-agonist component of N E  influenced by 
insulin. Repeated NE infusion showed no time- or vehicle 
effect. We conclude that regional hyperinsulinemia in the 
physiological range induces local vasodilation in the skel­
etal muscle vascular bed, but this vasodilation is not me­
diated through modulation of a- or p-adrenergic respon­
s iv en ess . Key Words: Insulin— a -A d ren o cep to r— p- 
Adrenoceptor— V as odilation.
Hyperinsulinemia as a counterpart of insulin re­
sistance is a prominent feature of associated cardio­
vascular risk factors as hypertension, obesity, dys- 
lipidemia, and non-insulin-dependent diabetes mel- 
litus (1,2). The nature and significance of this 
association, an issue of considerable pathophysio­
logical importance, is still unclear but may be re­
lated to the cardiovascular effects of insulin. Be­
sides its key role in the regulation of carbohydrate 
metabolism (3), insulin has important cardiovascu­
lar effects (4,5). Despite earlier reports that insulin 
was in itself capable of inducing hypertension (6), 
most recent reports have failed to confirm this (7,8). 
Indeed, in acute experiments in healthy subjects
(9,10) as well as in patients with hypertension (11), 
insulin has been shown to induce a vasodilator ef­
fect and not to increase systemic blood pressure 
(BP). Furthermore, several groups of researchers, 
including ourselves, have shown that during acute 
hyperinsulinemia the sympathetic nervous system 
is activated (9,11-13).
The mechanism of insulin’s effect on vascular 
tone has not yet been clarified (4), but an interaction 
with the autonomic nervous system seems obvious 
because insulin-induced stimulation of the sympa­
thetic nervous system does not lead to increases in 
BP, at least not in acute experiments. Thus, insulin- 
induced vasodilation could be explained by a de­
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creased sensitivity of the vascular bed to a-adrener- 
gic stimuli or an increased responsiveness to (3- 
adrenoceptor agonists. Indeed, various investiga­
tors have reported a change in responses to adre­
nergic stimuli deemed to be a modulatory effect of 
insulin. The reported results, however, are ex­
tremely controversial and show various differences 
in design: Studies in humans versus in animal 
(14,15), studies with systemic hyperinsulinemia (eu- 
glycemic clamp technique) versus studies with re­
gional hyperinsulinemia (16,17), systemic adminis­
tration of vasoactive drugs versus local administra­
tion  (1 8 ,1 9 ) , and great v a r ie ty  in drugs 
administered: norepinephrine (NE) (14-17,20-22), 
phenylephrine (PE) (18,23), angiotensin II (All) (15, 
16,19), isoproterenol (ISO) (24,25), and epinephrine 
(26). Furthermore, studies are performed in healthy 
humans as well as in disease states characterized by 
insulin resistance (20,27-29). In the presence of hy­
perinsulinemia, attenuated (15,18,22,23,30) un­
changed (14,20), and exaggerated (16,19,21), re­
sponses to the various vasoconstrictors have been 
reported, as have increased (24) and decreased (25) 
responses to the (3-adrenergic vasodilator ISO.
In the present study, we used the perfused fore­
arm technique to investigate whether acute hyper­
insulinemia affected vascular a- or p-adrenoceptor 
responsiveness in humans. Studying these two as­
pects together may be advantageous, because at dif­
ferent levels significant interactions and cross-talks 
do exist: Both endogenous catecholamines NE and 
epinephrine exhibit a- and (3-adrenoceptor affinity. 
Furthermore, stimulation of presynaptic a- and 
(3-adrenoceptors inhibits and stimulates NE release 
from sympathetic nerve endings, respectively (31). 
Finally, an eventual effect of insulin modulating the 
a-adrenoceptor-mediated vasoconstriction could 
be counterbalanced by a change in (3-adrenoceptor 
sensitivity, Our results convincingly show that in­
sulin has local vasodilator properties itself but does 
not affect the responsiveness to a- or (3-adrenocep­
tor stimulation.
METHODS 
Subjects
In all, 42 studies were performed in 33 healthy subjects 
(16 women, 17 men), aged 19-32 years (mean ±  SD, 23 ±  
3 years). All were normotensive [mean office BP after 
5-min rest in the supine position: systolic BP (SBP) 125 ±
11 mm Hg and diastolic BP (DBP) 75 ±  8  mm Hg], and 
normoglycemic and had a normal weight [body mass in­
dex (BMI) 22.5 ±  1.7 kg ■ m - 2 ]. All subjects had a neg­
ative family history of diabetes mellitus and hyperten­
sion. The participants were recruited by advertisement 
and received a small remuneration. All gave written in­
formed consent. The experimental protocol was ap­
proved by the local ethics committee.
Measurements
Forearm volum e was measured by water displacement. 
Forearm blood flow (FBF) was measured simultaneously
in both forearms by mercury-in-silastic strain-gauge ve­
nous occlusion plethysmography. The elbows and wrist 
were supported at or just above heart level. Strain gauges 
were attached around the forearm at the level o f the max­
imal diameter. One minute before the start of the FBF 
measurements, a pediatric cuff around the wrists was in­
flated to 100 mm Hg above the SBP level to ensure that 
the measurements referred only to the skeletal muscle 
vascular bed of the forearm. The collecting cuff around 
the upper arm was inflated to a supravenous pressure of 
40 mm Hg during eight heart cycles with the Hokanson 
E20 rapid cuff inflator (ECG-triggered). This cycle was 
repeated three to four times each minute. The strain 
gauges were connected with Hokanson’s EC4 plethysmo- 
graphs, and FBF was determined in mm/100 ml forearm 
volume per minute from the mean vertical deflection per 
minute divided by a 1% electrical calibration signal. FBF 
was expressed as milliliters per minute per deciliter of 
forearm volume, In addition, the ratio of the FBF in the 
infused arm to that in the control arm was calculated for 
each measurement (FBF ratio).
All experiments were performed in a temperature- 
controlled room (22°-24°C). Before, after 30 min, and af­
ter 60 min of local hyperinsulinemia, arterial and venous 
blood samples were taken for determination of glucose 
and insulin. Plasma glucose was measured by the glucose 
oxidation method (BeckmannR Glucose analyzer 2, 
Beckman Instruments, Fullerton, CA, U .S.A .); plasma 
insulin concentration was measured by a double-antibody 
in-house radioimmunoassay (RIA) with an interassay co­
efficient of variation of 6 .2 %.
Protocols
After a 12-h overnight fast, subjects came to the labo­
ratory. Under local anesthesia [0.3-0.4 ml lidocaine HC1 
2 0  mg/ml (Xylocaine 2%, Astra)], a 20-gauge, 2-inch cath­
eter (Angiocath, Becton Dickinson, Sandy, UT, U.S.A.) 
was inserted in the brachial artery and connected with an 
arterial pressure monitoring line (Viggo Spectramed, 
5269-129) to a Hewlett Packard 78353B monitor. Mean 
arterial pressure (MAP) was determined by an electroni­
cally integrated area under the brachial arterial pulse- 
wave form. The line was kept patent with saline infusion 
(3 ml/h with 2 U heparin/ml added). The dosages of drugs 
that administered were calculated per deciliter of forearm 
volume (ng • d l” 1 • min” 1). Moreover, a catheter (Ven- 
flon, 20 gauge, 32 mm) was retrogradely inserted in a deep 
ipsilateral forearm vein to obtain venous blood samples.
Effect o f  insulin on a -adrenergic responsiveness . First, 
after 30-min equilibration, baseline measurements were 
performed during concomitant intraarterial infusion of 
placebo (NaCl 0.9%, 50 |j l 1 • d l" 1 * min“ 1). In 12  sub­
jects, NE (Centrapharm) was infused in six sequential 
ascending doses into the brachial artery. Each concentra­
tion was prepared separately so that infusion volume did 
not change. The doses were 1.25, 5, 2 0 , 80, 160, and 240 
ng * d l" 1 ■ min” 1 (17). Each infusion lasted 4 min; in the 
third and fourth minute, MAP and FBF were measured. 
Between the first and second series of three dosage lev­
els, 15 min of rest were included to restrict the occlusion 
time of the hand circulation. To avoid eventual p-adre- 
noceptor-mediated effects of the intravascular NE infu­
sion (32), the nonselective p-blocking drug proprano­
lol w as in fused  co n co m ita n tly  in a d o se  o f  1 . 0  
fxl • d l“ 1 • min“ 1 from 2  min before until discontinuation
J  Cardiovasc Pharmacol™, Vol. 28, No. 2, 1996
I N S U L I N  A N D  R E S P O N SE  TO A D R E N E R G IC  S T IM U L I 247
of the NE infusion. After the final dose o f  N E, baseline 
measurements were repeated after 30-min equilibration. 
Subsequently, instead of NaCl 0.9%, insulin (Actrapid, 
Novo-Nordisk, Denmark) dissolved in an equal vol­
ume w as in fused  intraarterially in a d o se  of 0.3 
mU ' dl~* • min“ l. After 30 min of insulin infusion, mea­
surements were repeated, during ongoing insulin infu­
sion. Insulin was diluted twice by addition of human al­
bumin 20% (CBR Amsterdam) or autologous plasma. 
Subsequently, six increasing dosages of N E  were infused, 
with addition of propranolol, exactly as before the insulin 
administration.
Second, after an interval of at least 1 month, the pro­
tocol was repeated in 9 of the 12 subjects, but without the 
concomitant infusion of propranolol, to study the effects 
of NE alone. Unfortunately, 3 subjects were not mea­
sured a second time: 1 refused a second measurement, 1 
could not be cannulated again, and 1 could not be mea­
sured again due to lack of time. Because of these 3 drop­
outs, 3 other subjects were included in the second proto­
col to obtain a similar statistical power as in the first 
series.
Third, time control studies were made of a-adrenergic 
responsiveness. To exclude the possibility of down regu­
lation of a-adrenoceptor induced by the first infusion of 
multiple doses of NE, to correct for eventual systemic 
effects, and to exclude an effect of the time course and 
vehicle, control experiments were performed in 6  sub­
jects: NE was administered in six doses (similar to series 
I and II), first with placebo (NaCl 0.9%) and followed by 
a time period of saline + addition of autologous plasma 
(but not insulin); NE dose-response measurements were 
then repeated.
Effect o f  insulin on p-adrenergic responsiveness . in 12 
other subjects, an identical protocol was performed, but 
instead o f N E, ISO (isoproterenolsulfaat, 1 ml = 1 mg, 
RVG 51722 UR, Fresenius BV, ’s-Hertogenbosch, The 
Netherlands), a pure (3-adrenoceptor agonist, was infused 
in six increasing dosages of 0.03, 0 . 1 , 0.3, 1 .0 , 3.0 , and 10
ng • dl - l min - 1 each dose for 5 min. After comple­
tion of the last dose, at least 45-min equilibration was 
allowed before repeated baseline measurements were 
performed. Insulin was then again infused into the bra­
chial artery in exactly the same way and dose as in the 
first two studies, but for 60 min before readministration of  
the six isoproterenol dosages.
Calculations and statistical analysis
All descriptive data are expressed as mean ±  SD. FBF
is expressed as ng ■ dl - 1 min \  Furthermore, the ratio
of blood flow in the infused arm as compared with that in 
the control arm was calculated for each FBF measure­
ment. According to the literature, presentation of the data 
as the ratio of the left and right FBF is the best way to 
correct for eventual systemic changes due to arousal or to 
systemic effects of drugs (28,33). Therefore, the FBF ra­
tio was chosen as the preferential parameter and calcu­
lated percentage change was used for comparison. Often, 
FBF at the experimental side is also indicated to illustrate 
obtained flows. Differences between baseline flow pa­
rameters and flows during local hyperinsulinemia were 
calculated by Student’s paired t  test.
The NE (±  propranolol)/ISO dose-response curves ex­
pressed in percentage change in FBF ratio from baseline, 
before and during hyperinsulinemia, were evaluated by a
tw o-factor repeated-m easures a n a ly s is  o f  varian ce  
(ANOVA) to assess the effects o f  insulin, N E  (±  pro- 
pranolol)/ISO and the interaction o f  these agents. In the 9  
subjects in whom two experiments were performed (once 
with and once without propranolol), the differences in the 
individual responses were used to calculate a (3-adreno- 
ceptor-mediated vasodilator component of N E  infusion. 
When data were pooled (effect o f insulin/time), only the 
first obtained data set o f subjects who were studied twice  
was used for evaluation.
A p-value <0 .05  was considered statistically signifi­
cant, All statistical analyses were performed with the 
SPSS personal computer package. All results are mean ±  
SEM unless otherwise indicated,
RESULTS
Insulin and glucose concentrations during the study
During intraarterial infusion of insulin, deep ve­
nous forearm insulin concentration increased from 
65 ± 22 to 498 ±  48 pM, indicating regional physi­
ological hyperinsulinemia. In contrast, arterial insu­
lin levels did not change. After 30 min of local in­
sulin administration, venous plasma glucose con­
centration was decreased from 4.6 ± 0.3 to 3.8 ± 
0.6 mM, whereas arterial levels did not change 
(from 4.8 ± 0.3 to 4.7 ±  0.3 mM),
Effects of adrenergic stimulation on skeletal muscle 
blood flow
Regional infusion of propranolol in itself did not 
affect baseline flow (FBF ratio 1.08 ± 0.08 vs. 1,07 
± 0.09, p = NS). NE in combination with propran­
olol caused a dose-dependent decrease in flow 
(FBF ratio from 1.07 ±  0.09 to 0.22 ±  0.04, FBF 
from 1.7 ± 0.2 to 0.4 ± 0 . 1  ml ■ dl""1 • min“ 1 p <  
0.001) (Fig. 1). NE alone again induced a forearm 
vasoconstrictor response (FBF ratio from 1 .1 2  ±  
0.07 to 0.45 ±  0,07, FBF from 1.8 ±  0.2 to 0.8 ±  0.2 
ml • dl“ 1 ■ min"1, p <  0 . 0 0 1  for both) that was ini­
tially dose dependent, but the response to the high-
6.0
4.0
isoproterenol
o -  norepi alone 
norapi + prop
I
1.0
0.6
0.2  -
I  i  ‘ a -  ■  I *" 1 l  ■
B D1 D2 D3 D4 D5 D5
FIG. 1. Effect of six doses of norepinephrine (1.25, 5, 20, 80, 
160, and 240 ng • d l-1 • m in -1) with and without propranolol 
(1.0 jxl • d r 1 ■ m in '1), or isoproterenol (0.03, 0.1, 0 .3 ,1 .0 , 3.0, 
and 10 ng • dl
B, Baseline, D, Dose; norepi, norepinephrine; prop, propran­
olol.
- 1 m in"1) on forearm blood flow (FBF) ratio.
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FIG. 2. Difference between the decrease in forearm blood 
flow (FBF) during six increasing doses of norepinephrine 
(NE) alone and decrease in FBF during identical dosages of 
NE in combination with propranolol (prop). The decrease in 
FBF was larger when propranolol was added, presumably 
because of an intrinsic p-adrenergic vasodilatory effect of 
NE. This effect appeared to show a dose-dependent relation.
est NE dose (FBF ratio 0.52 ± 0 .11 , FBF 1.0 ± 0.3 
ml • d l~ l • m in~l) appeared to be less pronounced 
than that to the preceding dose. Moreover, the 
overall responses were smaller than those to NE in 
combination with propranolol (Fig. 1).
In the 9 subjects who underwent both experi­
ments, the responses to NE alone were significantly 
different from those to propranolol (p <  0 .0 0 1 ). 
Subtraction of the vasoconstrictor response to NE 
+ propranolol and the response to NE alone 
showed a dose-dependent vasodilatory component 
in the effect of NE, presumed to be (3-adrenocep- 
tor-mediated (it can be inhibited by propranolol) 
(34) (Fig. 2). ISO induced a dose-dependent vasodi­
lation (FBF ratio from 0.90 ± 0.08 to 5.16 ± 0.65, 
FBF from 1.7 ± 0.3 to 8.1 ±  0.8 ml * dl- 1  * min“ 1, 
p <  0.001) (Fig. 1), After this first series of vasoac­
tive drugs, flow parameters returned toward base­
line values: all data pooled (n — 33)—FBF ratio 
1.03 ±  0.04 and 1.11 ± 0.10 (p = 0.45), FBF 1.7 ±  
0 .1  and 1.9 ± 0,1 ml • dl- 1  * min” 1 (p = 0.18), be­
fore and after vasoactive drugs, respectively.
Effects of insulin on skeletal muscle blood flow
In 27 subjects, insulin was locally infused as part 
of the protocol. After 30 min of regional hyperinsu- 
linemia, an obvious increase in the FBF ratio (in­
fused/control arm) was observed from 1.16 ± 0 .1 2  
to 1.56 ± 0.15 (p = 0.009), FBF increased from 2 . 2
0.3 to 2.8 ±  0.4 ml ■ dl - 1 min - 1 (P 0.002).
Mean percentage increase in blood flow was 38 ±  
11%, p = 0.001, with a wide range ( — 23 to 
+  158%). In the subgroup of 9 subjects who had 
participated in both the NE alone and the NE in 
combination with propranolol experiments, there 
was no difference in the increase in FBF with insu­
lin alone, versus increase in FBF after previous pro­
pranolol administration (percentage increase 43 ±  
17 vs. 50 ±  12%, without and with propranolol, 
respectively, p = 0 .6 8 ).
Effects of insulin on adrenergic responsiveness
Due to the previous insulin-induced vasodilator 
response, baseline parameters before the two sets 
of experiments were not equal. To correct for these 
differences and for possible nonspecific systemic 
changes, we calculated percentage changes of FBF 
ratios, according to the literature (28) (described in 
the Materials and Methods section).
Percentage changes in FBF ratio during NE + 
propranolol were similar and not significantly dif­
ferent before and during hyperinsulinemia (maxi­
mum percentage decrease 79.5 ± 3.0% before insu­
lin vs. 75.5 ± 4.0% during hyperinsulinemia, p = 
0.25) (Fig. 3).
Similar results were observed for the percentage 
changes of the FBF ratios during insulin and NE 
administration alone (maximum percentage de­
crease 55.7 ± 8.7% before insulin vs. 57.4 ± 3.8% 
during insulin, p = 0.81). In time control studies, as 
shown in Fig. 4, repeated infusion of NE induced a 
reproducible degree of vasoconstriction.
In 9 subjects, experiments with both NE alone 
and with NE -f propranolol were performed. Va­
soconstriction with NE + propranolol was more 
intense than vasoconstriction with NE alone. Sub­
traction of the individual vasoconstrictor responses 
to NE from the first and the second study showed a 
vasodilator component of the NE administration 
(described in the Materials and Methods section). 
The results of this subtraction procedure for all six 
NE dosages showed a dose relation before as well 
as during hyperinsulinemia. The difference in per­
centage change in FBF ratio between NE + pro­
pranolol and NE alone was maximal 27 ± 9% before 
insulin versus maximal 18 ± 3% during insulin, p = 
0.41. Again therefore, this (3-adrenoceptor-medi­
ated vasodilator component was not significantly 
altered by regional hyperinsulinemia. Finally, the 
responses of FBF ratio during ISO infusion were 
identical before and during hyperinsulinemia (max-
o
«20 '
-40 '
-60 -
-80- placebo
insulin
1.25 20 80 160 240
norepinephrine (ng/dl/m in)
FIG. 3. Effect of six increasing doses of norepinephrine 
( + propranolol) on percentage decrease in forearm blood 
flow (FBF) ratio before and during hyperinsulinemia.
J Cardiovase Pharmacol™. VoL 28 , N o . 2, 1996
INSULIN AND RESPONSE TO ADRENERGIC STIMULI 249
2.0
1.5
1.0
0 .5
0.0
—  v — second series
— A *-■ firs t series
p=NS
-I-------------- 1--------------- 1--------- ----“ 1----------- ---- I--------------- 1--------------- \
B 1.25 5 20 80 160 240 
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FIG. 4. Effect of repeated administration of six increasing 
doses of norepinephrine ( + propranolol) on forearm blood 
flow (FBF) ratio.
imum percentage increase 524 ± 
vs. 441 ±  63% during insulin, p
8 8% before insulin 
= 0.19) (Fig. 5).
DISCUSSION
We confirmed that insulin administered locally in 
physiological concentrations induces vasodilation 
in forearm skeletal muscle. Our results also show 
that hyperinsulinemia in the physiological range 
does not attenuate the forearm vasoconstrictor re­
sponse to NE or the vasodilatory response to ISO. 
This conclusion is based on the comparable per­
centage responses of FBF ratio before as compared 
with during insulin administration. Indeed, evalua­
tion of the absolute changes after drug infusion 
would have shown a more pronounced response 
during hyperinsulinemia. However, as reported 
previously (28), the absolute decrease in FBF dur­
ing administration of a vasoconstrictor is signifi­
cantly correlated to the level of the baseline FBF 
(correlations in our study between mean decrease in 
FBF during combined NE/propranolol and baseline 
flow: r = 0.76 before insulin and r = 0.93 during 
insulin). Because insulin increased the baseline 
FBF significantly, the subsequent absolute NE- 
induced decrease in FBF was also increased, but 
nonspecifically. This view is further supported by 
the study of Neahring and colleagues (20), who 
showed that the absolute but not the relative re­
sponse to intrabrachial NE infusion was increased 
by regional infusion of the vasodilator drug sodium 
nitroprusside.
Neither were the responses to the p-adrenocep- 
tor-mediated vasodilator ISO affected by local hy­
perinsulinemia. With all these considerations taken
into account, our data suggest that insulin in phys­
iological concentrations shows no specific interac­
tion with a- or (3-adrenergic-stimulating agents at 
the level of the forearm vascular bed.
Vasodilatory effect of insulin
In acute experiments in humans, systemic insulin 
infusion with maintenance of euglycemia exerted a 
vasodilator effect in skeletal muscle (9,12,35). Al­
though controversial results have been reported af­
ter local insulin administration, recent reports 
mostly show a local vasodilatory effect as well 
(10,36). Two important aspects could explain part 
of the controversial findings. First, insulin-induced 
vasodilation apparently is not an acute effect, but 
instead is one of slow onset. Steinberg and associ­
ates infused insulin into the femoral artery and re­
ported a significant increase in femoral blood flow 
after 20 min but not after 10 min of infusion (37). We 
noted a clear increase in FBF after 30 min. In the 
group receiving ISO, insulin was infused for 60 min, 
but FBF did not increase from 30 to 60 min. Sec­
ond, the individual vasodilator response to insulin 
shows a high variability, in our study ranging from 
-2 3  to 4-158%, as has been reported by other in­
vestigators (10). This indicates that in studies with 
small sample sizes the effect could be missed due to 
a type 2 statistical error. Because of the many par­
ticipants, the insulin-induced vasodilation was 
highly significant in the current study.
Effect of insulin on
a-adrenoceptor-mediated vasoconstriction
Several reports have shown very controversial 
findings with regard to the effect of insulin on a-ad- 
renoceptor-mediated vasoconstriction. Results of 
several recent studies in vivo in humans, compara­
ble to ours, appear to be in contrast to our findings. 
Sakai and co-workers (18) did not observe a signif­
icant vasodilator effect of insulin infusion but re­
ported an attenuated a-adrenoceptor stimulation by
600 -
400 -
200
placebo 
m i  insulin
0
0.03 0.1 0 .3 1 10
iso p ro te reno l (ng /d l/m in )
FIG. 5. Effect of six increasing doses isoproterenol on per­
centage increase in forearm blood flow (FBF) ratio before 
and during hyperinsulinemia.
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PE. We believe that the contrasting results may be 
explained by slight but relevant differences in the 
design of the studies. Sakai and co-workers started 
the infusion of PE after 20 min of insulin infusion 
and evaluated the effect of insulin alone after 10 
min. Therefore, because the insulin-induced vasodi­
lation can be slow in onset, Sakai and co-workers 
(18) may have missed this effect. Assuming that the 
vasodilator effect occurred later, the attenuated re­
sponse to PE could be explained simply by the ad­
ditive effects of vasodilation by insulin and vaso­
constriction by PE. The same is true of the results 
of Lembo (30). On the contrary, results of other 
investigators, although in studies with a slightly dif­
ferent design, are in complete accord with ours
(14,20).
Effect of insulin on 
P-adrenoceptor-mediated vasodilation
Recent in vitro experiments have shown an insu- 
lin-mediated enhancement of vascular (3-adrenergic 
responsiveness to ISO (24). On the other hand, im­
paired forearm |3-adrenoceptor-mediated vasodila­
tion to isoproterenol has been described in patients 
with hypertension (25). Our experiments quite con­
vincingly show that acute local physiological hyper­
insulinemia in the human forearm vascular bed does 
not influence the sensitivity to the (5-adrenoceptor 
agonist isoproterenol. In addition, we provide fur­
ther indirect evidence for these findings: Our exper­
iments were performed with the endogenous neuro­
transmitter NE instead of PE or related a-adreno- 
ceptor agonists, especially because it is the most 
physiological method of investigating the effect of 
insulin on a-adrenoceptor sensitivity. However NE 
can induce (3-adrenoceptor-mediated vasodilation 
and also has vasoconstrictor properties (34,38). To 
study the pure a-effect, we performed the study 
twice, once with and once without a (3-adrenoceptor 
blocking agent. The last study was also performed 
to exclude an effect of insulin which could have 
been (3-adrenoceptor mediated, an effect that has 
been reported previously (39). By comparing the 
paired studies with and without propranolol, we 
were able to confirm the dose-dependent (13- 
adrenoceptor-mediated) vasodilator component of 
NE and were also able to confirm that this vasodi­
lator component was not influenced by regional hy­
perinsulinemia.
This finding further supports our conclusion that 
the vascular effects of the endogenous neurotrans­
mitter NE are not altered by increased insulin con­
centrations. Moreover, our results further show 
that the addition of a (3-adrenoceptor blocking agent 
is essential when NE is used to study pure a-adre- 
noceptor-mediated effects. Therefore, our results 
appear to be significant because most studies of the 
interaction between insulin and NE did not correct
for eventual fi-adrenoceptor-mediated effects of 
NE (14-17,20,21).
We confirmed that regional infusion of insulin in­
duced a unilateral increase in FBF, indicating a lo­
cal mechanism. The mechanism of action of this 
direct vasodilator effect of insulin is not completely 
clear (40), but our results indicate that it is not re­
lated to modulation of a- or ^-adrenergic respon­
siveness. Other mechanisms probably are involved; 
recent reports indicate a nitric oxide-dependent 
pathway (37,41).
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